FDA Brief

Warning letters Drugs

FDA warning letter to

Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

High riskIssued Apr 29Posted May 19Center for Drug Evaluation and Research (CDER)

FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

What happened

FDA inspected the All India Institute of Medical Sciences in Bhubaneswar, Odisha, India, from March 17 to March 20, 2025, reviewing Dr. Mishra's conduct of a bioequivalence study of doxorubicin hydrochloride liposome injection 20 mg/10 mL run for Qilu Pharmaceutical (Hainan) Co., Ltd. FDA found that all three enrolled subjects were given Aprecap (aprepitant), a moderate CYP3A4 inhibitor that the study protocol prohibited because it affects how the study drug is processed in the body. FDA also found the informed consent form told subjects the study drug was already approved and shown to be effective, without saying whether that applied to the test or the reference product.

What FDA found

  1. All three subjects received Aprecap (aprepitant), a CYP3A4 inhibitor the protocol banned during the study, and the investigator said this was the oncology department's usual practice before chemotherapy.

    21 CFR 312.60
  2. The consent form stated that the study drug was already approved and that there was evidence it was effective in the subject's disease, which could lead people to mistaken conclusions about the investigational product.

    21 CFR 50.20
  3. The consent form never made clear whether the approval and effectiveness statements referred to the test product or the reference product.

    21 CFR 50.20

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of the actions taken to prevent similar violations in the future, or explain with supporting information why you believe you complied.

Who should pay attention

  • sponsors and contract research organizations running bioequivalence trials at this site
  • clinical investigators who sign off on sponsor-written consent forms
  • sites enrolling cancer patients in drug studies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk